Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Spherix. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Spherix's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Spherix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Professional Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Spherix's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Spherix's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Spherix's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Spherix is high growth as no earnings estimate data is available.
Unable to determine if Spherix is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Spherix's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Anthony C. Hayes has been the Chief Executive Officer and Principal Accounting Officer of Spherix Incorporated since September 10, 2013 and March 10, 2017 respectively and serves as its President and Principal Financial Officer. Mr. Hayes is a Director of Hoth Therapeutics, Inc. since June 2017. Mr. Hayes co-founded Jansome IP Management LLC in August 2012 and served as its Portfolio Manager. Mr. Hayes served as a Portfolio Manager of Jansome IP Management LLC, Asset Management Arm. He is a Litigation Consultant to several IP litigation companies. He is an Attorney and was a Partner of Nelson Mullins Riley & Scarborough LLP. He served as the Chief Executive Officer for North South Holdings Inc. since March 2012 and also served as its President. Prior to law school, he worked on the floor of the NYMEX on Wall Street. He has successfully monetized patents through a wide variety of monetization methods, including price arbitrage and litigation licensing brought against companies such as Cisco, Broadcom, Nokia, Ericsson, Tellabs and Alcatel-Lucent. He has been a Director of Spherix Incorporated since September 10, 2013. He served as a Director of North South Holdings Inc. since 2013. Mr. Hayes has received national recognition during his legal career, including: Special recognition by President George W. Bush, American Board of Trial Advocates Young Lawyer of the Year; and City of Columbia 20 Under 40. Mr. Hayes holds a Juris Doctor from Tulane University School of Law in 1995 and B.A. degree in Economics from Mary Washington College in Fredericksburg, Virginia in 1990.
Anthony's compensation has increased whilst company is loss making.
Anthony's remuneration is about average for companies of similar size in Germany.
VP & General Counsel
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Spherix board of directors is about average.
Board of Directors
Robert Vander Zanden
Independent Chairman of the Board
Member of Scientific Advisory Board
Member of Technology Advisory Board
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Spherix Incorporated, a biotechnology development company, focuses on developing small-molecule anti-cancer therapeutics. The company engages in the development of therapeutic drugs for the treatment of various cancers including pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Its portfolio includes KPC-34 for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and DHA-dFdC drug for chemotherapy treatment and pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.